Lentinan

Drug Profile

Lentinan

Alternative Names: LC 33; YM 09222

Latest Information Update: 06 May 2016

Price : $50

At a glance

  • Originator Ajinomoto
  • Developer Ajinomoto; EA Pharma; Taiho Pharmaceutical
  • Class Antineoplastics; Antivirals; Beta Glucans
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • No development reported Breast cancer; Colorectal cancer; HIV infections; Liver cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 30 Nov 2005 No development reported - Phase-III for Lung cancer in Japan (IV)
  • 30 Nov 2005 No development reported - Phase-II for HIV infections treatment in USA (IV)
  • 30 Nov 2005 No development reported - Phase-II for Liver cancer in Japan (Intra-arterial)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top